Development of the bisquaternary oxime HI-6 toward clinical use in the treatment of organophosphate nerve agent poisoning.
The traditional therapeutic treatment of organophosphate cholinesterase inhibitor (nerve agents) poisoning consists of co-treatment with an antimuscarinic (atropine) and a reactivator of inhibited acetylcholinesterase (AChE), which contains a nucleophilic oxime function. Two oximes are presently widely available for clinical use, pralidoxime and obidoxime (toxogonin), but both offer little protection against important nerve agent threats. This has highlighted the real need for the development and availability of more effective oximes for human use, a search that has been going on for up to 30 years. However, despite the demonstration of more effective and safe oximes in animal experiments, no additional oximes have been licensed for human use. HI-6, (1-[[[4(aminocarbonyl)-pyridinio]methoxy]methyl]-2(hydroxyimino)pyridinium dichloride; CAS 34433-31-3) has been studied intensively and has been proved effective in a variety of species including non-human primates and appears from clinical experience to be safe in humans. These studies have led to the fielding of HI-6 for use against nerve agents by the militaries of the Czech republic, Sweden, Canada and under certain circumstances the Organisation for the Prohibition of Chemical Weapons. Nevertheless HI-6 has not been granted a license for clinical use, must be used only under restricted guidelines and is not available for civilian use as far as is known. This article will highlight those factors relating to HI-6 that pertain to the licensing of new compounds of this type, including the mechanism of action, the clinical and pre-clinical demonstration of safety and its efficacy against a variety of nerve agents particularly in non-human primates, since no relevant human population exists. This article also contains important data on the use of HI-6 in baboons, which has not been available previously. The article also discusses the possibility of successful therapy with HI-6 against poisoning in humans relative to doses used in non-human primates and relative to its ability to reactivate inhibited human AChE.
Lundy
Paul M
PM
Therapeutic Response, Medicine Hat, Alberta, Canada.
Raveh
Lily
L
Amitai
Gabriel
G
D000818:Animals; D000931:Antidotes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002619:Chemical Warfare Agents / Q000506:poisoning*; D002801:Cholinesterase Reactivators / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008253:Macaca mulatta; D008297:Male; D062025:Organophosphate Poisoning; D009943:Organophosphorus Compounds / Q000037:antagonists & inhibitors; D010091:Oximes; D010215:Papio; D011041:Poisoning / Q000188:drug therapy* / Q000503:physiopathology; D011726:Pyridinium Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000931:Antidotes; D002619:Chemical Warfare Agents; D002801:Cholinesterase Reactivators; D009943:Organophosphorus Compounds; D010091:Oximes; D011726:Pyridinium Compounds; C022870:asoxime chloride